The University of Southampton
University of Southampton Institutional Repository

Development of genetic testing for breast, ovarian and colorectal cancer predisposition: a step closer to targeted cancer prevention

Development of genetic testing for breast, ovarian and colorectal cancer predisposition: a step closer to targeted cancer prevention
Development of genetic testing for breast, ovarian and colorectal cancer predisposition: a step closer to targeted cancer prevention
Individuals who inherit a high penetrance cancer susceptibility gene represent a population in which cancer diagnoses occur at younger ages and much more frequently than in the general population. Screening regimens aimed at early detection of cancer may reduce cancer mortality but in order to reduce cancer incidence, surgery and medical therapies have been advocated. In high genetic risk patients intervention, either surgical or medical, at young ages may provide long term protection against cancer and co-morbidities will be low. The use of genetic testing for high risk predisposition genes to refine risk estimates and inform choices about cancer prevention is now readily available in many countries and routinely used to target cancer prevention strategies. Surgical approaches to cancer prevention are currently the mainstay in many conditions where a high risk is identified but medical preventions strategies also have demonstrated some efficacy in lowering cancer risk. Using the genetic status of an individual to target cancer treatment and prevent recurrence is increasingly gaining momentum and entering the arena in the form of targeted clinical trials using both well known cytotoxic drugs and novel targeted agents. Translation of this new knowledge into beneficial clinical care strategies requires more research and robust cancer prevention clinical trials will inevitably require large collaborative international endeavour.
genetic predisposition, high-risk, prevention, clinical utility, breast cancer, colon cancer, polyposis, lynch syndrome, chemotherapy
1389-4501
1974-1982
Eccles, Diana
5b59bc73-11c9-4cf0-a9d5-7a8e523eee23
Eccles, Diana
5b59bc73-11c9-4cf0-a9d5-7a8e523eee23

Eccles, Diana (2011) Development of genetic testing for breast, ovarian and colorectal cancer predisposition: a step closer to targeted cancer prevention. Current Drug Targets, 12 (13), 1974-1982. (doi:10.2174/138945011798184209). (PMID:21158705)

Record type: Article

Abstract

Individuals who inherit a high penetrance cancer susceptibility gene represent a population in which cancer diagnoses occur at younger ages and much more frequently than in the general population. Screening regimens aimed at early detection of cancer may reduce cancer mortality but in order to reduce cancer incidence, surgery and medical therapies have been advocated. In high genetic risk patients intervention, either surgical or medical, at young ages may provide long term protection against cancer and co-morbidities will be low. The use of genetic testing for high risk predisposition genes to refine risk estimates and inform choices about cancer prevention is now readily available in many countries and routinely used to target cancer prevention strategies. Surgical approaches to cancer prevention are currently the mainstay in many conditions where a high risk is identified but medical preventions strategies also have demonstrated some efficacy in lowering cancer risk. Using the genetic status of an individual to target cancer treatment and prevent recurrence is increasingly gaining momentum and entering the arena in the form of targeted clinical trials using both well known cytotoxic drugs and novel targeted agents. Translation of this new knowledge into beneficial clinical care strategies requires more research and robust cancer prevention clinical trials will inevitably require large collaborative international endeavour.

This record has no associated files available for download.

More information

e-pub ahead of print date: 2010
Published date: 1 December 2011
Keywords: genetic predisposition, high-risk, prevention, clinical utility, breast cancer, colon cancer, polyposis, lynch syndrome, chemotherapy
Organisations: Cancer Sciences, Medicine, Clinical Trials Unit

Identifiers

Local EPrints ID: 180043
URI: http://eprints.soton.ac.uk/id/eprint/180043
ISSN: 1389-4501
PURE UUID: 0fa8daf8-1ac9-4f82-9886-9f9d32a8de73
ORCID for Diana Eccles: ORCID iD orcid.org/0000-0002-9935-3169

Catalogue record

Date deposited: 06 Apr 2011 14:07
Last modified: 15 Mar 2024 02:40

Export record

Altmetrics

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×